X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus which was recently approved by USFDA. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus and company believes the regulatory review could be completed by mid-2024.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 110 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus and company believes the regulatory review could be completed by mid-2024.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 110 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
The financing will be used to further invest in R&D, as well as continued market access preparations and potential commercialization of Valneva’s VLA1553, a live-attenuated vaccine candidate for active immunisation and prevention of disease caused by chikungunya virus.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Deerfield Management Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 17, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, If approved, VLA1553 would expand Valneva’s existing commercial vaccines portfolio.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
VLA15 is the only Lyme disease vaccine candidate under development. It is a multivalent protein subunit vaccine which targets the outer surface protein A (OspA) of borrelia burgdorferi, the bacteria that cause lyme disease.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 120 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 120 countries. It has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 120 countries, has been designed by deleting a part of the chikungunya virus genome.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The VLA1553 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
The final analysis confirmed very high level of seroprotection, with 98.9% of participants achieving protective levels of chikungunya virus-neutralizing antibodies one month after receiving a live-attenuated single vaccination of VLA1553.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The primary objective of the trial is to evaluate safety and immunogenicity following a single vaccination with VLA1553. Participants will be evaluated after 28 days and followed up to twelve months.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Details:
VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
In the Phase 1 clinical trial of VLA1553, Valneva observed development of antibodies to chikungunya virus resulting in 100% seroconversion of the 120 healthy participants.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2021
Details:
VLA1553 is the only chikungunya vaccine candidate in Phase 3 clinical trials at this time. 410 participants aged 18 to 45 years have been randomized in the Phase 3 trial VLA1553-302 and will be followed for a total of six months.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
This study will run in parallel to the ongoing, pivotal Phase 3 study, VLA1553-301, which includes the determination of seroprotection based on an immunological surrogate.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2021
Details:
Under the collaboration, Valneva will transfer its chikungunya vaccine, VLA1553, technology to Instituto Butantan, who will develop, manufacture and commercialize the vaccine in LMICs.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA1553
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Instituto Butantan
Deal Size: $23.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 25, 2021
Details:
The main Phase 3 pivotal trial will be, subject to detailed protocol review, a double-blinded, placebo-controlled, multi-center study in approximately 4,000 healthy adults.
Lead Product(s): VLA1553
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
